19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells

Parkin, 2001, Cancer burden in the year 2000. The global picture, Eur J Cancer, 37, S4, 10.1016/S0959-8049(01)00267-2 Llovet, 2003, Hepatocellular carcinoma, Lancet, 362, 1907, 10.1016/S0140-6736(03)14964-1 Bruix, 1996, Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure, Gastroenterology, 111, 1018, 10.1016/S0016-5085(96)70070-7 Llovet, 1999, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation, Hepatology, 30, 1434, 10.1002/hep.510300629 Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 Llovet, 1999, Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials, Hepatology, 29, 62, 10.1002/hep.510290145 Schwartz, 2002, Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials, Lancet Oncol, 3, 593, 10.1016/S1470-2045(02)00873-2 Villanueva, 2007, Genomics and signaling pathways in hepatocellular carcinoma, Semin Liver Dis, 27, 55, 10.1055/s-2006-960171 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Llovet, 2008, Molecular targeted therapies in hepatocellular carcinoma, Hepatology, 48, 1312, 10.1002/hep.22506 Tanaka, 1982, 1Alpha,25-dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60), Biochem J, 204, 713, 10.1042/bj2040713 Chen, 2003, Vitamin D and prostate cancer prevention and treatment, Trends Endocrinol Metab, 14, 423, 10.1016/j.tem.2003.09.004 Stewart, 2004, Vitamin D and prostate cancer, Exp Biol Med, 277, 10.1177/153537020422900401 Gonzalez-Sancho, 2006, Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells, Anticancer Res., 26, 2669 Colston, 2006, Vitamin D status and breast cancer risk, Anticancer Res, 26, 2573 Zhang, 2006, Vitamin D receptor is a novel drug target for ovarian cancer treatment, Curr Cancer Drug Targets, 6, 229, 10.2174/156800906776842939 Kawa, 1997, Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines, Br J Cancer, 76, 884, 10.1038/bjc.1997.479 Chiang, 2009, Vitamin D for the prevention and treatment of pancreatic cancer, World J Gastroenterol, 15, 3349, 10.3748/wjg.15.3349 Ghous, 2008, Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study, Anticancer Res, 28, 3757 Chiang, 2009, Fish oil enhances the antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 on liver cancer cells, Anticancer Res, 29, 3591 Bouillon, 1995, Non-hypercalcemic pharmacological aspects of vitamin D analogs, Biochem Pharmacol, 50, 577, 10.1016/0006-2952(95)00121-F Guyton, 2001, Cancer chemoprevention using natural vitamin D and synthetic analogs, Annu Rev Pharmacol Toxicol, 41, 421, 10.1146/annurev.pharmtox.41.1.421 Akhter, 2001, 1alpha,25-Dihydroxyvitamin D3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2, ANZ J Surg, 71, 414, 10.1046/j.1440-1622.2001.02147.x Ono, 2003, Efficient synthesis of 2-modified 1alpha,25-dihydroxy-19-norvitamin D3 with Julia olefination: high potency in induction of differentiation on HL-60 cells, J Org Chem, 68, 7407, 10.1021/jo034787y Flanagan, 2009, Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer, Anticancer Res, 29, 3547 Chen, 2007, Evaluation of C-2-substituted 19-nor-1alpha,25-dihydroxyvitamin D3 analogs as therapeutic agents for prostate cancer, J Steroid Biochem Mol Biol, 103, 717, 10.1016/j.jsbmb.2006.12.009 Chen, 2000, The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer, Clin Cancer Res, 6, 901 Chen, 1995, The antiproliferative and differentiative activities of 1,25-dihydroxyvitamin D3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes, J Invest Dermatol, 104, 113, 10.1111/1523-1747.ep12613601 Ouyang, 2005, Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1–S phase transition in human keratinocytes, Cancer Res, 65, 9287, 10.1158/0008-5472.CAN-05-0469 Vermes, 2000, Flow cytometry of apoptotic cell death, J Immunol Methods, 243, 167, 10.1016/S0022-1759(00)00233-7 Jaruga, 1998, Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes, FEBS Lett, 433, 287, 10.1016/S0014-5793(98)00919-3 Chawla, 2001, Nuclear receptors and lipid physiology: opening the X-files, Science, 294, 1866, 10.1126/science.294.5548.1866 Evans, 1988, The steroid and thyroid hormone receptor superfamily, Science, 240, 889, 10.1126/science.3283939 Tsai, 1994, Molecular mechanisms of action of steroid/thyroid receptor superfamily members, Annu Rev Biochem, 63, 451, 10.1146/annurev.bi.63.070194.002315 Stumpf, 1979, Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid, Science, 206, 1188, 10.1126/science.505004 Norman, 2008, From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health, Am J Clin Nutr, 88, 491S, 10.1093/ajcn/88.2.491S Schwartz, 2005, Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer, Clin Cancer Res, 11, 8680, 10.1158/1078-0432.CCR-05-1237 Gulliford, 1998, A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer, Br J Cancer, 78, 6, 10.1038/bjc.1998.434 Evans, 2002, A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer, Br J Cancer, 86, 680, 10.1038/sj.bjc.6600162 Finlay, 2001, A phase one study of the hepatic arterial administration of 1,25-dihydroxyvitamin D3 for liver cancers, J Gastroenterol Hepatol, 16, 333, 10.1046/j.1440-1746.2001.02398.x Dalhoff, 2003, A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma, Br J Cancer, 89, 252, 10.1038/sj.bjc.6601104 Perman, 1990, 1α, 25-dihydroxy-19-nor-vitamin D3. A novel vitamin D-related compound with potential therapeutic activity, Tetrahedron Lett, 31, 1823, 10.1016/S0040-4039(00)98795-1 Perman, 1991, Novel synthesis of 19-nor-vitamin D compounds, Tetrahedron Lett, 32, 7663, 10.1016/0040-4039(91)80559-O Slatopolsky, 1995, A new analog of calcitriol, 19-nor-1α,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia, Am J Kidney Dis, 26, 852, 10.1016/0272-6386(95)90455-7 Llach, 1998, Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2, Am J Kidney Dis, 32, S48, 10.1053/ajkd.1998.v32.pm9808143 Sicinski, 2002, 2-Ethyl and 2-ethylidene analogues of 1alpha,25-dihydroxy-19-norvitamin D(3): synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain, J Med Chem, 45, 3366, 10.1021/jm020007m Hourai, 2006, Probing a water channel near the A-ring of receptor-bound 1alpha,25-dihydroxyvitamin D3 with selected 2 alpha-substituted analogues, J Med Chem, 49, 5199, 10.1021/jm0604070 Powers, 2004, E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis, Mol Cancer Res, 2, 203, 10.1158/1541-7786.203.2.4 Krtolica, 1998, Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities, Oncogene, 17, 2295, 10.1038/sj.onc.1202159 Luo, 2009, EB1089 induces Skp2-dependent p27 accumulation, leading to cell growth inhibition and cell cycle G1 phase arrest in human hepatoma cells, Cancer Invest, 27, 29, 10.1080/07357900802438569 Yang, 2003, Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm, J Biol Chem, 278, 46862, 10.1074/jbc.M306340200 Yang, 2002, Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer, Mol Cell Endocrinol, 186, 69, 10.1016/S0303-7207(01)00671-2 Flores, 2010, Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition, Endocrinology, 151, 896, 10.1210/en.2009-1116 Ylikomi, 2002, Antiproliferative action of vitamin D, Vitam Horm, 64, 357, 10.1016/S0083-6729(02)64010-5 Chaudhry, 2001, The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells, Cancer Chemother Pharmacol, 47, 429, 10.1007/s002800000251 Gown, 2002, Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3, J Histochem Cytochem, 50, 449, 10.1177/002215540205000401 Duan, 2003, Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts, J Pathol, 199, 221, 10.1002/path.1289 Resendes, 2004, Apoptosis in lymphoid organs of pigs naturally infected by porcine circovirus type 2, J Gen Virol, 85, 2837, 10.1099/vir.0.80221-0